If Moderna Inc’s COVID-19 vaccine proves to be at least 70 percent effective, the company plans to seek emergency authorization for its use in high-risk groups, the company’s chief executive told Reuters. Moderna’s vaccine candidate – mRNA-1273 – is nearing the finish line in its push to enroll 30,000 individuals in a late-stage trial of a novel coronavirus vaccine. An independent safety board will take a first look at Moderna’s data as soon as a total of 53 people in the trial become infected with COVID-19. …read more
Source:: Yahoo Finance
